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Introduction and context {#s01}
========================

Approximately 1-5% of peripheral blood T cells express the γδ T-cell receptor instead of the conventional αβ T-cell receptor \[[@bib-001]\]. The αβ versus γδ T-cell lineage commitment during intrathymic T-cell development seems to be controlled by the signal strength provided to the γδ T-cell receptor \[[@bib-002]\]. In healthy donors, most blood γδ T cells carry a specific T-cell receptor composed of Vγ9 and Vδ2 elements. In addition to effector functions shared with αβ T cells, the Vγ9Vδ2 T cells can acquire professional antigen-presenting capacity characteristic of dendritic cells \[[@bib-003]\]. In contrast to αβ T cells, Vγ9Vδ2 T cells do not see processed antigenic peptides presented by major histocompatibility complex molecules, but rather recognize small phosphorylated non-peptide molecules ('phosphoantigens') produced by many microorganisms but also by transformed eukaryotic cells \[[@bib-004],[@bib-005]\]. While microbial phosphoantigens are active at pico- to nanomolar concentrations, micromolar concentrations of the eukaryotic phosphoantigen isopentenyl pyrophosphate (IPP) are required for γδ T-cell activation. Such high concentrations are not achieved in the mevalonate pathway of isoprenoid synthesis used in non-transformed cells. Interestingly, human Vγ9Vδ2 T cells can kill a broad variety of epithelial tumor and leukemia/lymphoma cells \[[@bib-006],[@bib-007]\]. The sensitivity of tumor cells to γδ T-cell-mediated killing is increased upon treatment of tumor cells with aminobisphosphonates (N-BPs), drugs that are used in clinical practice for the treatment of osteoporosis and bone metastasis in cancer patients \[[@bib-008]\]. N-BPs inhibit the IPP-processing enzyme farnesyl diphosphate synthase (FPPS), thereby leading to an accumulation of IPP, which is then sensed by the γδ T cells \[[@bib-009]\]. γδ T cells are poor producers of interleukin-2 (IL-2), which is required for expansion of γδ T cells. Therefore, attempts to activate tumor-reactive γδ T cells endogenously by treating patients with N-BPs must take into consideration an appropriate supply of IL-2. Alternative strategies consider the adoptive transfer of *in vitro* expanded tumor-reactive γδ T cells \[[@bib-010]-[@bib-014]\].

Recent advances {#s02}
===============

The critical role of FPPS in the control of intracellular IPP levels, and thus of the sensitivity of tumor cells toward γδ T-cell killing, has been recently demonstrated using short hairpin RNA-mediated knock-down of FPPS \[[@bib-015]\]. Knock-down of FPPS caused tumor cells, which otherwise were not recognized by γδ T cells, to be susceptible to γδ T-cell killing \[[@bib-015]\]. Therefore, Vγ9Vδ2 T cells recognize and kill tumor cells on the basis of the unbalanced isoprenoid metabolic pathway in transformed cells, a pathway that is stable in non-malignant cells.

The discovery that N-BPs activate γδ T cells by inhibiting FPPS, thereby leading to accumulation of IPP, has paved the way for proof-of-principle studies to activate γδ T cells in patients with advanced cancer. In a phase I clinical trial, Dieli and colleagues \[[@bib-016]\] treated patients with hormone-refractory prostate cancer with a standard application of the N-BP zoledronate (4 mg intravenous infusion every 21 days) either with or without additional low-dose (6 × 10^5^ IU) subcutaneous application of IL-2. Various parameters, including subset analysis of γδ T cells, and serum levels of prostate-specific antigen and cytokines, were monitored over time. Although the two cohorts comprised only a few patients, statistically significant effects of zoledronate plus IL-2 on the mobilization and effector cell maturation of γδ T cells were recorded. Very importantly, the two cohorts showed distinct clinical outcomes, with clinical responses seen in six of nine patients treated with zoledronate plus IL-2 but only in one of nine patients treated with zoledronate alone. Interestingly, a correlation between favorable outcome at 12 months and γδ T-cell numbers or functional status (or both) was observed \[[@bib-016]\]. Similarly, Wilhelm and colleagues had previously shown that the combined application of N-BP plus low-dose IL-2 can induce objective tumor responses in patients with lymphoid malignancies \[[@bib-017]\]. Together, these studies support the view that application of N-BPs plus IL-2 is safe, induces *in vivo* activation/maturation of γδ T cells, and may have beneficial effects in advanced cancer ([Figure 1a](#fig-001){ref-type="fig"}).

![Approaches to immunotherapy with γδ T cells\
**(a)** N-BPs inhibit farnesyl diphosphate synthase (FPPS), thus preventing processing of isopentenyl pyrophosphate (IPP) to farnesyl diphosphate (FPP). This leads to accumulation of IPP which then activates Vγ9Vδ2 T cells. Vγ9Vδ2 T cells require exogenous interleukin (IL)-2 for cellular expansion. The combined application of N-BP plus IL-2 leads to *in vivo* activation of γδ T cells. **(b)** Alternatively, γδ T cells can be activated *in vitro* with N-BP or synthetic phosphoantigens in the presence of antigen-presenting cells (APC) and can be subsequently expanded to large cell numbers by an exogenous supply of IL-2 for subsequent adoptive transfer into cancer patients. The cell preparation can be performed under GMP (Good Manufacturing Practice) conditions.](1757-5931-0002-0000000045-g001){#fig-001}

In a case study reported by Laggner *et al*. \[[@bib-018]\], regression of lung and bone metastases was observed in a patient with advanced stage melanoma upon systemic treatment with zoledronate and localized radiotherapy. Although γδ T-cell subsets were analyzed, it is difficult to ascertain a substantial role of γδ T-cell activation in the resolution of metastases in this single case, particularly since IL-2 was omitted in the treatment of this patient \[[@bib-018]\].

In addition to their γδ T-cell activating properties, N-BPs also exhibit direct anti-tumor activities by both inhibiting proliferation and inducing apoptosis in tumor cells \[[@bib-019]\]. While zoledronate seems to be the most potent γδ T-cell-activating substance among the N-BPs licensed for clinical application \[[@bib-009]\], derivatives of zoledronate with further improved γδ T-cell-stimulating capacity and enhanced direct anti-tumor activity are under development \[[@bib-020]\]. Such modified N-BPs might also exert improved *in vivo* activation of γδ T cells when given to patients together with IL-2.

An alternative and not mutually exclusive γδ T-cell-based immunotherapeutic strategy is the adoptive transfer of *in vitro* expanded Vγ9Vδ2 T cells from tumor patients ([Figure 1b](#fig-001){ref-type="fig"}). Recently, efficient protocols for the large-scale *in vitro* expansion of Vγ9Vδ2 T cells based on stimulation with synthetic phosphoantigens \[[@bib-011],[@bib-013],[@bib-014]\] or zoledronate \[[@bib-021]\] have been established. First results indicate that the repetitive adoptive transfer of *in vitro* expanded γδ T cells is well tolerated and may induce anti-tumor responses in patients with solid tumors, including renal cell carcinoma \[[@bib-013],[@bib-014]\] and myeloma \[[@bib-012]\].

Implications for clinical practice {#s03}
==================================

The protocol developed by Dieli *et al*. \[[@bib-016]\] for the *in vivo* activation of γδ T cells based on zoledronate plus low-dose IL-2 application is ready to be explored in larger clinical trials and in other tumor entities with poor prognosis, for example, pancreatic ductal adenocarcinoma where it might be combined with standard regimens such as gemcitabine. It is conceivable that this protocol can be further improved, for instance, by combination with tumor-targeting monoclonal antibodies. Along this line, it has been shown that B-cell lymphoma or breast tumor cell killing by Fcγ receptor-expressing γδ T cells is enhanced in the presence of targeting antibodies rituximab (CD20) or trastuzumab (HER2/neu), respectively \[[@bib-022]\]. Moreover, a γδ T-cell-stimulating synthetic phosphoantigen was found to enhance the depletion of CD20^+^ B cells by rituximab in a non-human primate model *in vivo*, pointing to the possible use of phosphoantigen plus anti-CD20 antibodies in the treatment of CD20^+^ leukemias and lymphomas \[[@bib-023]\]. Furthermore, cytokines promoting homeostatic proliferation and survival of T cells, such as IL-15 \[[@bib-024]\], or cytokines potentiating the cytolytic activity and pro-inflammatory response, such as IL-21 \[[@bib-025]\], might be combined with IL-2 or used instead of IL-2. This could be considered both for *in vivo* application together with N-BPs and for optimization of *in vitro* expansion of γδ T cells. In addition, future study protocols might include the combination of *in vivo* activation of γδ T cells (by N-BP or phosphoantigen plus IL-2) followed by the adoptive transfer of *in vitro* expanded γδ T cells, Finally, it should be stressed that γδ T-cell-based immunotherapy is not expected to replace established therapeutic protocols. Rather, it might offer additional benefit to the patient, for instance, in combination with conventional chemotherapy \[[@bib-026]\].
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